Shelley Secor-Socha, B.S.
Shelley Secor-Socha graduated from RIT in 1994 with a Bachelor of Science degree in Biotechnology. Prior to graduating Shelley was well versed in lab techniques having completed multiple internships and employment with Lederle-Praxis Biologics (LPB) beginning in September of 1992. As a member of the Hybridoma Facility at LPB Shelley produced monoclonal antibodies supporting multiple research programs. Shelley was hired full time in the Preclinical Immunobiological Services Departmentat Wyeth (former LPB) in 1994 just prior to graduation. For the next 10 years Shelley dealt with a variety of vaccine research programs developing ELISAs and bioassays, analyzing preclinical samples in support of research and product development projects. During this time Shelley became an expert in laboratory quality control and regulatory compliance. In an effort to upgrade Wyeth labs to a GLP environment, Shelley wrote and executed validation protocols for high tech lab equipment, performed assay method qualification/validations and wrote standard operating procedures. Shelley is well acquainted with efficiency and quality improvement In an effort to increase output and quality of preclinical data, Shelley ordered, set up and qualified 4 new robotics units for the laboratory following GLP guidelines.
Shelley joined the Rochester Human Immunology Center Core laboratory as a technical associate II in February of 2005 where her first assignment was to train on the ELISPOT in an effort to offer it as a service of the RHIC lab. She has also worked to evaluate new technologies and methods for the RHIC including the introduction of Luminex Technology to the laboratory and training investigators on the new technology. Shelley has also developed several multichromatic panels for evaluating the phenotype T regulatory cells and also for sorting for CD4+ T memory, effector cells, T regulatory cells and also CD8 T memory populations. Shelley developed the process, organized, and coordinated the laboratory for the Biodefense contract for immunocompromised populations. Another crucial accomplishment has been creating standard operation procedures for use within the RHIC and to other investigators within the University. She has also performed a physical inventory of the RHIC sample storage, created tracking logs for sample requests and organized a new method to keep the inventory current. In 2007, she was qualified by through Immune Tolerance Network (ITN) to isolate and cryopreserve patient samples for TrialNet studies.